Coordinatore | AURORA MEDICAL LTD
Organization address
address: NEWPORT DRIVE 17 FISHBOURNE contact info |
Nazionalità Coordinatore | United Kingdom [UK] |
Sito del progetto | http://www.endure-fp7.com |
Totale costo | 1˙483˙378 € |
EC contributo | 1˙140˙149 € |
Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
Code Call | FP7-SME-2008-1 |
Funding Scheme | BSG-SME |
Anno di inizio | 2009 |
Periodo (anno-mese-giorno) | 2009-10-01 - 2011-12-31 |
# | ||||
---|---|---|---|---|
1 |
AURORA MEDICAL LTD
Organization address
address: NEWPORT DRIVE 17 FISHBOURNE contact info |
UK (CHICHESTER) | coordinator | 174˙184.00 |
2 |
FINSBURY (DEVELOPMENT) LIMITED
Organization address
address: "MOLE BUSINESS PARK, Randalls Road 13" contact info |
UK (LEATHERHEAD) | participant | 334˙674.10 |
3 |
HUNT DEVELOPMENTS (UK) LTD
Organization address
address: Holmbush Industrial Estates Units 15-18 contact info |
UK (Midhurst) | participant | 237˙335.00 |
4 |
MEDICOAT AG
Organization address
address: Almuesenacherstrasse 2A contact info |
CH (Magenwil) | participant | 211˙071.00 |
5 |
ALA ORTHO SRL
Organization address
address: Via Dell'Innovazione 9 contact info |
IT (MILANO) | participant | 72˙481.00 |
6 |
Invibio Ltd
Organization address
address: Hillhouse International contact info |
UK (Thornton Cleveleys) | participant | 35˙491.00 |
7 |
CERAMTEC AG
Organization address
address: Fabrikstrasse 23-29 contact info |
DE (PLOCHINGEN) | participant | 30˙001.00 |
8 |
BIOMATECH SAS
Organization address
address: Rue Pasteur - ZI de L'Islon contact info |
FR (CHASSE SUR RHONE) | participant | 13˙152.00 |
9 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 11˙541.00 |
10 |
UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
UK (SOUTHAMPTON) | participant | 10˙293.00 |
11 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | participant | 9˙926.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Each year in Europe there are:- • 800000 hip operations costing approximately €1,942 per/implant, worth over €1.5 billion • Hip implant operations are rising by approximately 15%. • Currently 10% of all the prosthesis implanted are in patients under 55 years of age of which 33% of these will fail within 16 years with a further 20% of implant fitted to over 55’s failing with in 20 years requiring revisional surgery costing €2.3 billion per annum. Treatment of younger patients with severe hip disease using a conventional THR presents a challenge with the rate of success being very low, (most failing within 16 years). To over come this Finsbury help develop the MoM BHR resurfacing hip with a survival rate of 93% over a conventional THR. However, studies have reported high concentrations of Co & Cr in the serum and/or urine of patients with MoM resurfacing implants. Studies have shown that increased levels of Co & Cr cause caners such as leukaemia and are linked with myocardiopathy. During the course of this project we intend to overcome these problems by developing a ceramic one ceramic or ceramic on polymer resurfacing hip. Like that of the MOM prosthesis will only cover the femoral head thus retaining all of the desirable properties associated with retaining an intact femur.'
Increasing the durability of hip prosthetics is sometimes accompanied by the release of hazardous substances into the body. EU-funded scientists developed novel ceramic-on-polymer prosthetics for a superior implant.
Highly Sustainable and Effective Production of Innovative Low Cost Vacuum Insulation Panels for Zero Carbon Building Construction
Read MoreA framework for mobile wallets that provides the security levels QAA1-4 in a TSM architecture supporting the use of e-Identity cards on the mobile phone
Read More